Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Quarterly turnaround ⢠Negative cash flow ⢠Elevated valuation PGEN's sharp quarterly profitability and liquidity improvement is tempered by persistent cash burn, high leverage, massive accumulated deficits, dilution risk, and a valuation that appears difficult to justify.
Price Behavior
Key Price Behavior Insights: ⢠Cooling momentum ⢠Key support test ⢠Overhead resistance Support Level: $6.68â$6.80; stronger support $6.49â$6.55 Resistance Level: $7.42â$7.44 PGEN is still higher over the last month but weakening below $6.95; reclaiming $6.95/$7.20 would improve momentum, while a break below $6.68 risks $6.49â$6.55 support beneath $7.42â$7.44 resistance.
Sentiment & News
Key News Insights: ⢠Papzimeos Sales Surge ⢠Quarterly Profitability Achieved ⢠Pipeline Expansion Progress Precigen's surging Papzimeos revenue, profitability, and institutional interest strengthen its growth outlook, while pipeline progress supports longer-term upside.
AI Summary
PGEN's $53.1M PAPZIMEOS revenue quarter and reported profitability mark a credible shift to a commercial-stage growth story, but investors should require operating cash-flow breakeven by year-end before underwriting the premium valuation, given single-product concentration, debt, and dilution risk.
Description
Precigen, Inc. is a U.S.-based biotechnology company that discovers and develops gene and cell therapies and related disease-modifying therapeutics. The company also supports regenerative medicine and reproductive technologies, including genetically engineered swine and embryo transfer services, and maintains a suite of platform technologies for gene delivery, regulated expression, non-viral integration and microbial delivery of therapeutic proteins. Precigen has a history of collaboration and licensing arrangements with multiple partners, was founded in 1998, and changed its name from Intrexon Corporation in January 2020; it is headquartered in Germantown, Maryland.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Aug 21 | Aug 28 | PGEN | Precigen, Inc. | PAPZIMEOS Q2 revenue more than doubled to $53.1 million, EPS of $0.05 beat an expected loss, and FDA exclusivity runs through 2032. Shares gained about 34% over 21 sessions, with $7.44 the near-term breakout level. | Closed | -3.5% |